Md. biotech outlines path for blood cancer drug, including in China
Rockville biotech GlycoMimetics Inc. has entered into a license agreement worth $189 million or more with a West Coast company.
The deal gives cancer therapy biopharma Apollomics Inc. of Foster City, California exclusive rights to develop and commercialize GlycoMimetics' blood cancer drug in greater China, which encompasses mainland China, Hong Kong, Taiwan and Macau, the company said Monday. GlycoMimetics (NASDAQ: GLYC) w ill receive $9 million in cash upfront and around $180 million in milestone…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Sara Gilgore Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | China Health | Health Management | Hong Kong Health | Macau Health | Taiwan Health